Trump Orders $50M to Fast-Track Psychedelic Treatments

A stroke of the president's pen just opened new doors for thousands of Americans struggling with mental health conditions that haven't responded to traditional treatment.

President Trump signed an executive order Saturday directing at least $50 million toward psychedelic drug research, with podcaster Joe Rogan and former Navy SEAL Marcus Luttrell present at the Oval Office ceremony. The order aims to speed up medical reviews for drugs like ibogaine, psilocybin, and MDMA.

The timing matters. Veterans groups have pushed for years to expand access to psychedelic treatments, especially ibogaine, a plant-based compound some say has helped with post-traumatic stress. Luttrell, who wrote the memoir "Lone Survivor," praised the drug at the signing: "It absolutely changed my life for the better."

Ibogaine comes from a West African plant traditionally used in Bwiti religious ceremonies. It currently sits in the federal government's most restrictive category for illegal drugs, alongside heroin and LSD. That classification has blocked most American research for decades, even as small studies showed promise.

The executive order directs the Department of Health and Human Services to fund state programs developing psychedelic treatments for serious mental illness. The FDA will also issue "national priority" vouchers for three psychedelics this week, allowing faster approval if they meet safety standards.

This week marks another milestone: the FDA is clearing the way for the first-ever human trials of ibogaine in the United States. Previous research stalled over concerns about potential heart complications, but new safety protocols have addressed those risks.

Why This Inspires

This represents rare bipartisan agreement in Washington on a health issue. Advocacy groups across the political spectrum have united around expanding mental health treatment options, particularly for veterans facing limited choices.

The research investment could help millions of Americans with treatment-resistant depression, PTSD, and anxiety disorders. Traditional antidepressants don't work for everyone, and some patients wait years trying different medications with little relief.

Rogan recounted texting Trump about ibogaine before the signing. The president's response was immediate: "Sounds great. Do you want FDA approval? Let's do it." That kind of quick action on a long-stalled issue gives hope to patients and researchers who've waited decades for progress.

Health Secretary Robert F. Kennedy Jr. had previously pledged to ease medical access to psychedelics. Saturday's order turns that promise into policy with real funding attached.

The $50 million investment and streamlined approval process could put effective treatments in patients' hands within months instead of years.